The United States Food and Drug Administration (USFDA) has issued a Form 483 with two observations to Biocon’ Bengaluru API facility.
The drug regulator conducted a post-approval and GMP inspection of the company’s small molecules API manufacturing facility in Bengaluru between February 20 and 26, 2020.
“At the conclusion of the inspection the agency issued a Form 483, with two observations, which are procedural in nature,” Biocon said in a regulatory filing on Thursday.
The company said that it would respond to the drug regulator with a corrective and preventive action plan in a timely manner.
“We remain committed to global standards of quality and compliance,” the company’s spokesperson said in the statement.
The shares of Biocon fell 1.49 percent to Rs 294.24 on the BSE at 9:20 am.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Arvind Kejriwal challenges BJP to arrest entire AAP, leads protest walk to BJP headquarters
May 19, 2024 12:26 PM
Terror attacks in Kashmir raise concerns ahead of May 20 and May 25 election
May 19, 2024 12:15 PM
AAP protest today: Delhi traffic police issues traffic advisory, security at BJP headquarters beefed up
May 19, 2024 11:26 AM
BJP is planning to ban RSS, says Shiv Sena (UBT) chief Uddhav Thackeray
May 18, 2024 8:01 PM